Tag: Glenmark

Nasal Spray
Glenmark To Sell Nasal Spray To Treat Adult Covid-19 Patients

The nasal spray is designed to kill the coronavirus in the upper airways and when it is sprayed over nasal mucosa, it (nasal spray) acts as a physical and chemical barrier against the virus, preventing it (virus) from incubating and spreading to the lungs.

  • Wednesday, 09 February 2022
Favipiravir-Glenmark-Pharma
Glenmark Starts Phase-3 Clinical Trials On Favipiravir For COVID Patients In India

New Delhi: Glenmark Pharmaceuticals said on Tuesday that it has initiated phase – three clinical trials on antiviral Favipiravir for COVID-19 patients in India. COVID-19 patients from over 10 leading government and private hospitals in India are being enrolled for the study. The trial completion and study results are expected by July-August this year. Glenmark […]

  • Saturday, 17 April 2021
Anti-viral-Drug
Glenmark to start trial combining 2 anti-viral drugs on Covid patients in India

New Delhi: Glenmark Pharmaceuticals announced on Tuesday that it will commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India. Glenmark has received approval from the Indian regulator to initiate the study. The combination study which will be called the […]

  • Friday, 16 April 2021
COVID-19-Medicine-Favipirav
India Pharma Company Glenmark Launches COVID19 Drug At Rs 103

Mumbai: Glenmark Pharmaceuticals on Saturday launched antiviral drug Favipiravir for treatment of mild-to-moderate Covid-19 cases after it received the Indian drug regulator’s approval. It will be available under the brand name FabiFlu as a prescription-based medication for Rs 103 per tablet, with a recommended dose of 1,800 mg twice a day on day 1 and […]

  • Thursday, 15 April 2021
Fabiflu
Fighting COVID-19: Fabiflu More Economical & Effective Treatment Option, Claims Glenmark

New Delhi: In a strong rebuttal to the drug regulator, Glenmark Pharma said it has been at the receiving end of careless, unsubstantiated allegations that are devoid of merits related to Covid drug, Fabiflu. In a reply to V.G. Somani, Directorate General of Health Services, Central Drugs Standard Control Organisation, Glenmark has responded to allegations […]

  • Wednesday, 14 April 2021
Fabiflu
Covid-19 Treatment: Glenmark Announces 400 mg 'FabiFlu'

New Delhi: Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to introduce a 400 mg version of oral antiviral – FabiFlu — for the treatment of mild to moderate Covid-19 in India. It was the first Indian company to commercially launch an antiviral drug – Favipiravir with brand name […]

  • Wednesday, 14 April 2021
scrollToTop